Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates

The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater bio...

Full description

Bibliographic Details
Main Authors: Mahmood Barani, Fakhara Sabir, Abbas Rahdar, Rabia Arshad, George Z. Kyzas
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Nanomaterials
Subjects:
Online Access:https://www.mdpi.com/2079-4991/10/9/1696
_version_ 1797555230435442688
author Mahmood Barani
Fakhara Sabir
Abbas Rahdar
Rabia Arshad
George Z. Kyzas
author_facet Mahmood Barani
Fakhara Sabir
Abbas Rahdar
Rabia Arshad
George Z. Kyzas
author_sort Mahmood Barani
collection DOAJ
description The fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.
first_indexed 2024-03-10T16:44:31Z
format Article
id doaj.art-08720676212a4dc49808152b1ce48e19
institution Directory Open Access Journal
issn 2079-4991
language English
last_indexed 2024-03-10T16:44:31Z
publishDate 2020-08-01
publisher MDPI AG
record_format Article
series Nanomaterials
spelling doaj.art-08720676212a4dc49808152b1ce48e192023-11-20T11:42:16ZengMDPI AGNanomaterials2079-49912020-08-01109169610.3390/nano10091696Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent UpdatesMahmood Barani0Fakhara Sabir1Abbas Rahdar2Rabia Arshad3George Z. Kyzas4Department of Chemistry, Shahid Bahonar University of Kerman, Kerman 7616914111, IranInstitute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, HungaryDepartment of Physics, Faculty of Science, University of Zabol, Zabol 538-98615, IranDepartment of Pharmacy, Quaid-i-Azam University, Islamabad 45320, PakistanDepartment of Chemistry, International Hellenic University, 65404 Kavala, GreeceThe fabrication and development of nanomaterials for the treatment of prostate cancer have gained significant appraisal in recent years. Advancements in synthesis of organic and inorganic nanomaterials with charge, particle size, specified geometry, ligand attachment etc have resulted in greater biocompatibility and active targeting at cancer site. Despite all of the advances made over the years in discovering drugs, methods, and new biomarkers for cancer of the prostate (PCa), PCa remains one of the most troubling cancers among people. Early on, effective diagnosis is an essential part of treating prostate cancer. Prostate-specific antigen (PSA) or serum prostate-specific antigen is the best serum marker widely accessible for diagnosis of PCa. Numerous efforts have been made over the past decade to design new biosensor-based strategies for biomolecules detection and PSA miniaturization biomarkers. The growing nanotechnology is expected to have a significant effect in the immediate future on scientific research and healthcare. Nanotechnology is thus predicted to find a way to solve one of the most and long-standing problem, “early cancer detection”. For early diagnosis of PCa biomarkers, different nanoparticles with different approaches have been used. In this review, we provide a brief description of the latest achievements and advances in the use of nanoparticles for PCa biomarker diagnosis.https://www.mdpi.com/2079-4991/10/9/1696nanomaterialscancerprostatetreatmentdiagnosis
spellingShingle Mahmood Barani
Fakhara Sabir
Abbas Rahdar
Rabia Arshad
George Z. Kyzas
Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
Nanomaterials
nanomaterials
cancer
prostate
treatment
diagnosis
title Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
title_full Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
title_fullStr Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
title_full_unstemmed Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
title_short Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates
title_sort nanotreatment and nanodiagnosis of prostate cancer recent updates
topic nanomaterials
cancer
prostate
treatment
diagnosis
url https://www.mdpi.com/2079-4991/10/9/1696
work_keys_str_mv AT mahmoodbarani nanotreatmentandnanodiagnosisofprostatecancerrecentupdates
AT fakharasabir nanotreatmentandnanodiagnosisofprostatecancerrecentupdates
AT abbasrahdar nanotreatmentandnanodiagnosisofprostatecancerrecentupdates
AT rabiaarshad nanotreatmentandnanodiagnosisofprostatecancerrecentupdates
AT georgezkyzas nanotreatmentandnanodiagnosisofprostatecancerrecentupdates